What Is This?
Longevity science is the multidisciplinary study of aging and how to slow, stop, or reverse it. Once considered fringe, it's now a serious scientific field with billions in funding, rigorous research programs, and the attention of mainstream medicine.
The core insight driving the field: aging isn't just "wear and tear" — it's a biological process with identifiable mechanisms that might be targetable with interventions. If we can understand why cells age, we might be able to do something about it.
This isn't about living forever or uploading minds. Modern longevity research focuses on "healthspan" — extending the years of healthy, functional life. The goal is more good years, not just more years.
Why Does It Matter?
Demographic time bomb: Developed nations are aging rapidly. By 2050, one in six people globally will be over 65. Healthcare systems face unsustainable burdens from age-related disease.
Quality of life: The last decades of life often involve decline — cognitive impairment, frailty, chronic disease. Extending healthspan means more years of independent, fulfilling life.
Economic implications: If people could work productively into their 80s and 90s (by choice), retirement systems could be rethought. Healthcare spending could potentially decrease if age-related diseases were delayed.
Scientific maturity: The field has moved from speculation to clinical trials. Drugs are being tested. Biomarkers are being developed. This is real science now.
Philosophical questions: If we can significantly extend healthy life, should we? What about inequality of access? Population growth? The field forces us to confront deep questions.
Key People & Players
Research Institutions:
- Buck Institute — Oldest dedicated aging research center (Novato, CA)
- Harvard/David Sinclair Lab — NAD+ research, epigenetic reprogramming
- Unity Biotechnology — Senolytic drugs to clear damaged cells
- Altos Labs — $3B startup focused on cellular reprogramming, founded 2022
Key Researchers:
- David Sinclair (Harvard) — NAD+ and resveratrol research; popular science communicator
- Aubrey de Grey — Controversial but influential advocate; proposed SENS framework
- Cynthia Kenyon (Calico) — Discovered genes that regulate aging in worms
- Steve Horvath — Developed epigenetic "clocks" to measure biological age
Companies:
- Calico (Alphabet/Google) — Secretive, well-funded aging research
- Altos Labs — Backed by Bezos, focusing on reprogramming
- Loyal — Longevity drugs for dogs (as a pathway to human applications)
- Rejuvenate Bio — Gene therapies for aging
The Current State
The field has converged on several "hallmarks of aging" — biological processes that drive decline:
- Genomic instability — DNA damage accumulates
- Telomere attrition — Chromosome caps shorten
- Epigenetic alterations — Gene regulation changes
- Loss of proteostasis — Protein quality control fails
- Mitochondrial dysfunction — Cellular energy production declines
- Cellular senescence — "Zombie cells" accumulate and cause inflammation
- Stem cell exhaustion — Regenerative capacity decreases
- Altered intercellular communication — Signaling goes haywire
What's being tested (human trials):
- Metformin (TAME trial) — Diabetes drug with potential anti-aging effects
- Senolytics — Drugs that clear senescent cells (dasatinib + quercetin)
- Rapamycin — mTOR inhibitor with lifespan effects in animals
- NAD+ precursors — NMN and NR supplements (results mixed)
What works (with evidence):
- Caloric restriction (strong animal evidence, hard for humans)
- Exercise (robust, multi-system benefits)
- Sleep quality (underrated)
- Not smoking, moderate alcohol
- Managing chronic disease
What's promising but unproven:
- Most supplements (including resveratrol, NMN)
- Metformin for non-diabetics
- Young blood transfusions
- Most "biohacking" interventions
Best Resources to Learn More
- "Lifespan" by David Sinclair — Accessible overview, though critics say it oversells
- "Why We Age" — SENS Research Foundation — Technical but comprehensive
- Peter Attia's "The Drive" podcast — Deep interviews with longevity researchers
- "Longevity FAQ" by Laura Deming — Concise overview from a longevity investor
- Aubrey de Grey TED talks — Provocative framing of aging as engineering problem
Sources
- "The Hallmarks of Aging" — Cell (2013), López-Otín et al. (foundational paper)
- TAME trial documentation and FDA discussions
- National Institute on Aging research summaries
- Interviews with researchers from Buck Institute and Harvard
- Clinical trial registrations from ClinicalTrials.gov
- Peter Attia's podcast episodes on specific interventions